CL2014001138A1 - Metodo para el tratamiento de una neoplasia linfoproliferativa administrando una dosis unica diaria continua del compuesto n-(3-{[(3-{[2-cloro-5-(metoxi) fenil]amino} quinoxalin-2-il) amino] sulfonil} fenil)-2-metilalaninamida. - Google Patents

Metodo para el tratamiento de una neoplasia linfoproliferativa administrando una dosis unica diaria continua del compuesto n-(3-{[(3-{[2-cloro-5-(metoxi) fenil]amino} quinoxalin-2-il) amino] sulfonil} fenil)-2-metilalaninamida.

Info

Publication number
CL2014001138A1
CL2014001138A1 CL2014001138A CL2014001138A CL2014001138A1 CL 2014001138 A1 CL2014001138 A1 CL 2014001138A1 CL 2014001138 A CL2014001138 A CL 2014001138A CL 2014001138 A CL2014001138 A CL 2014001138A CL 2014001138 A1 CL2014001138 A1 CL 2014001138A1
Authority
CL
Chile
Prior art keywords
phenyl
amino
methylalaninamide
quinoxalin
sulfonyl
Prior art date
Application number
CL2014001138A
Other languages
English (en)
Inventor
Arthur Decillis
Joanne Lager
Original Assignee
Sanofi Sa
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001138(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa, Exelixis Inc filed Critical Sanofi Sa
Publication of CL2014001138A1 publication Critical patent/CL2014001138A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014001138A 2011-11-01 2014-04-30 Metodo para el tratamiento de una neoplasia linfoproliferativa administrando una dosis unica diaria continua del compuesto n-(3-{[(3-{[2-cloro-5-(metoxi) fenil]amino} quinoxalin-2-il) amino] sulfonil} fenil)-2-metilalaninamida. CL2014001138A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553990P 2011-11-01 2011-11-01
US201161568189P 2011-12-08 2011-12-08

Publications (1)

Publication Number Publication Date
CL2014001138A1 true CL2014001138A1 (es) 2014-08-01

Family

ID=47295148

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001138A CL2014001138A1 (es) 2011-11-01 2014-04-30 Metodo para el tratamiento de una neoplasia linfoproliferativa administrando una dosis unica diaria continua del compuesto n-(3-{[(3-{[2-cloro-5-(metoxi) fenil]amino} quinoxalin-2-il) amino] sulfonil} fenil)-2-metilalaninamida.

Country Status (21)

Country Link
US (2) US20140303172A1 (es)
EP (1) EP2773353B1 (es)
JP (1) JP6013498B2 (es)
KR (1) KR20140096083A (es)
CN (2) CN104302294A (es)
AU (2) AU2012332486A1 (es)
BR (1) BR112014010492A2 (es)
CA (1) CA2854159A1 (es)
CL (1) CL2014001138A1 (es)
CR (1) CR20140253A (es)
DO (1) DOP2014000092A (es)
EA (1) EA201490905A1 (es)
EC (1) ECSP14002014A (es)
HK (1) HK1201480A1 (es)
IL (1) IL232398A0 (es)
MX (1) MX2014005249A (es)
NI (1) NI201400037A (es)
PE (1) PE20141794A1 (es)
SG (1) SG11201401961UA (es)
WO (1) WO2013067141A1 (es)
ZA (1) ZA201403258B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010492A2 (pt) 2011-11-01 2017-04-25 Exelixis Inc n-(3-{[(3-{[2-cloro-5-(metóxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inibidor de fosfatidilinositol 3-cinase para o tratamento de malignidades linfoproliferativas
AR092501A1 (es) * 2012-09-13 2015-04-22 Sanofi Sa Compuestos cristalinos
KR20150079745A (ko) 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP5270353B2 (ja) * 2005-10-07 2013-08-21 エクセリクシス, インク. ホスファチジルイノシトール3−キナーゼインヒビターとその使用方法
US8247408B2 (en) 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
CN101395155A (zh) 2005-10-07 2009-03-25 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
EP2056829B9 (en) 2006-08-16 2012-09-26 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
EP2139484B9 (en) 2007-04-10 2014-06-11 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
US8481001B2 (en) * 2007-04-11 2013-07-09 Exelixis, Inc. Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer
US20100150827A1 (en) 2007-04-11 2010-06-17 Exelixis, Inc Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
CN101711249A (zh) 2007-04-11 2010-05-19 埃克塞里艾克西斯公司 作为PI3K-α的抑制剂用于治疗癌症的吡啶并[2,3-D]嘧啶-7-酮化合物
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CA2712267A1 (en) * 2008-01-15 2009-07-23 Wyeth Llc 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
EP2350070A1 (en) 2008-09-30 2011-08-03 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k and mtor
WO2010120998A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
KR20120034666A (ko) 2009-05-22 2012-04-12 엑셀리시스, 인코포레이티드 증식성 질환에 대한 벤족사제핀 기반 p13k/mt0r의 억제제
CA2763008A1 (en) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
AU2011274510A1 (en) * 2010-07-09 2013-01-24 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
TWI617560B (zh) 2010-09-14 2018-03-11 伊塞利克斯公司 PI3Kδ 抑制劑以及其應用和生產方法
WO2012037204A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
EP2444084A1 (en) * 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
WO2012065057A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
EP2640367A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
EP2640366A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012071519A1 (en) 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
US20140073628A1 (en) 2010-11-24 2014-03-13 Kenneth D. Rice Benzoxazepines asn inhibitors of p13k/m tor and methods of their use and manufacture
JP2013544827A (ja) 2010-11-24 2013-12-19 エクセリクシス, インク. PI3K/mTORの阻害剤としてのベンゾオキサゼピン類ならびにそれらの使用法および製造法
US20140378436A9 (en) 2010-11-24 2014-12-25 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture
BR112013012961A2 (pt) 2010-11-24 2019-09-24 Exelixis Inc benzoxazepinas como inhibidores de mtor e métodos de seu uso e fabricação
TW201311683A (zh) 2011-04-29 2013-03-16 Exelixis Inc 使用吡啶并嘧啶酮pi3k/mtor抑制劑治療淋巴瘤之方法
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
BR112014010492A2 (pt) 2011-11-01 2017-04-25 Exelixis Inc n-(3-{[(3-{[2-cloro-5-(metóxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inibidor de fosfatidilinositol 3-cinase para o tratamento de malignidades linfoproliferativas
FR3008620A1 (fr) * 2013-07-22 2015-01-23 Sanofi Sa Formulation de comprime d'un inhibiteur de phosphatidylinositol 3-kinase
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators

Also Published As

Publication number Publication date
EA201490905A1 (ru) 2014-11-28
AU2012332486A1 (en) 2014-06-19
AU2017219131A1 (en) 2017-09-28
HK1201480A1 (en) 2015-09-04
US20140303172A1 (en) 2014-10-09
JP2014532709A (ja) 2014-12-08
IL232398A0 (en) 2014-06-30
JP6013498B2 (ja) 2016-10-25
DOP2014000092A (es) 2015-02-15
CN107375289A (zh) 2017-11-24
KR20140096083A (ko) 2014-08-04
ECSP14002014A (es) 2015-11-30
EP2773353B1 (en) 2018-09-05
MX2014005249A (es) 2015-03-05
EP2773353A1 (en) 2014-09-10
US20170296529A1 (en) 2017-10-19
US10328069B2 (en) 2019-06-25
ZA201403258B (en) 2015-11-25
CN104302294A (zh) 2015-01-21
BR112014010492A2 (pt) 2017-04-25
PE20141794A1 (es) 2014-12-17
WO2013067141A1 (en) 2013-05-10
CR20140253A (es) 2014-10-28
SG11201401961UA (en) 2014-05-29
CA2854159A1 (en) 2013-05-10
NI201400037A (es) 2014-12-22

Similar Documents

Publication Publication Date Title
HK1217487A1 (zh) 用於治療成癮的作為乙醛脫氫酶- 抑制劑的 -氧基- -二氫-吡啶- -基 -芐基 -苯甲酰胺衍生物
GT201400022A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
EA201490419A1 (ru) Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания
EA201391072A1 (ru) Производные фтор-пиридинона, полезные в качестве антибактериальных агентов
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
CL2014000468A1 (es) Compuestos derivados del acido 2-oxo-6-(fenil/heteroaril)l-1,2-dihidropiridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para el alivio de una infeccion bacteriana.
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
EA201591064A1 (ru) Новые производные пиридина
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
NZ702346A (en) Carbamate/urea derivatives
MX342153B (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
CL2014001138A1 (es) Metodo para el tratamiento de una neoplasia linfoproliferativa administrando una dosis unica diaria continua del compuesto n-(3-{[(3-{[2-cloro-5-(metoxi) fenil]amino} quinoxalin-2-il) amino] sulfonil} fenil)-2-metilalaninamida.
EA201200123A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
CR20130522A (es) Inhibidores de la péptido desformilasa
EA201301136A3 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
AR092627A1 (es) Derivados glucopiranosidos de urea
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).
AR098134A1 (es) Compuestos de urea
EA201301235A1 (ru) Новый способ синтеза 3-(2-бром-4,5-диметоксифенил)пропаннитрила и применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
CO6382120A2 (es) Compuestos ciclopropilo
EA201300281A2 (ru) Новый способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
UA117655C2 (uk) Спосіб синтезу 3-(2-бромо-4,5-диметоксифеніл)пропаннітрілу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою
UA110849C2 (uk) Сполуки для лікування та профілактики респіраторного синцитіального вірусного захворювання